If you have been reading about Ac-LKKTETQ and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-19. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
== Early life and education == In 1974, Eaton graduated from Montana State University with a Bachelor of Science in Pre-Medical Sciences. Under the guidance of Curtis Klaassen and John Doull, he earned a Ph.D. in pharmacology and toxicology at the University of Kansas Medical Center in 1978. In 1979, he joined the faculty at the University of Washington after completing a postdoctoral fellowship in toxicology at the same institution after earning his Ph.D.
== Qualifications == The Constitution of Myanmar sets the principle qualifications that the candidate must meet to be eligible for the office of the President. in Chapter 1: The President, Part I: The Federation of Myanmar in the Constitution of Myanmar. President has to be:
Preventing DAMP release – proapoptotic therapies, platinums, ethyl pyruvate Neutralizing or blocking DAMPs extracellularly – anti-HMGB1, rasburicase, sRAGE, etc. Blocking the DAMP receptors or their signaling – RAGE small molecule antagonists, TLR4 antagonists, antibodies to DAMP-R DAMPs can be used as biomarkers for inflammatory diseases and potential therapeutic targets. For example, increased S100A8/A9 is associated with osteophyte progression in early human osteoarthritis, suggesting that S100 proteins can be used as biomarkers for the diagnosis of the progressive grade of osteoarthritis. Furthermore, DAMP can be a useful prognostic factor for cancer. This would improve patient classification, and a suitable therapy would be given to patients by diagnosing with DAMPs. The regulation of DAMP signaling can be a potential therapeutic target to reduce inflammation and treat diseases. For example, administration of neutralizing HMGB1 antibodies or truncated HMGB1-derived A-box protein ameliorated arthritis in collagen-induced arthritis rodent models. Clinical trials with HSP inhibitors have also been reported. For nonsmall-cell lung cancer, HSP27, HSP70, and HSP90 inhibitors are under investigation in clinical trials. In addition, treatment with dnaJP1, which is a synthetic peptide derived from DnaJ (HSP40), had a curative effect in rheumatoid arthritis patients without critical side effects. Taken together, DAMPs can be useful therapeutic targets for various human diseases, including cancer and autoimmune diseases.
Sources: en.wikipedia.org
=== History === Black pepper has been known to Indian cooking since at least 2000 BCE. J. Innes Miller notes that pepper was grown in southern Thailand and in Malaysia starting in early 10th to the 11th century, when the South Indian kings began to extend their empire. The crop was brought to East Malaysia in 1840 by Chinese settlers; its most important source was India, particularly the Malabar Coast, in what is now the state of Kerala. The lost ancient port city of Muziris of the Chera Dynasty, famous for exporting black pepper and various other spices, is mentioned in a number of classical historical sources for its trade with the Roman Empire, Egypt, Mesopotamia, Levant, and Yemen. The ancient history of black pepper is often interlinked with (and confused with) that of long pepper, the dried fruit of closely related Piper longum. The Romans knew of both and often referred to either as just piper. In fact, the popularity of long pepper did not entirely decline until the discovery of the New World and of chilli peppers. Chilli peppers—some of which, when dried, are similar in shape and taste to long pepper—were easier to grow in a variety of locations more convenient to Europe. Before the 16th century, pepper was being grown in Java, Sunda, Sumatra, Madagascar, Malaysia, and everywhere in Southeast Asia. These areas traded mainly with China, or used the pepper locally. Ports in the Malabar area also served as a stop-off point for much of the trade in other spices from farther east in the Indian Ocean.
==== Liver injury ==== The prosecution argued that liver damage found at the post‑mortem of Child O could only be explained by deliberate harm, contrary to the original pathologist's view that the injury was natural. A senior perinatal pathologist who later reviewed the case said she had seen similar liver injuries arise naturally and described the prosecution expert's position as "naive". Published research documents hundreds of comparable cases occurring naturally in neonates. A joint report by two neonatologists working with Letby's legal team argued that the injury was worsened when a doctor accidentally punctured the liver by misplacing a needle. The prosecution pathologist and an independent expert interviewed by the BBC both said there was no evidence of needle trauma, although the BBC's expert also considered deliberate harm "unlikely". The Lee panel concluded that the doctor's needle may have penetrated the liver but considered it "highly likely" that the initial injury resulted from a traumatic delivery. They described the prosecution's blunt-force trauma hypothesis as "implausible". Neonatologist Mike Hall, who was instructed by Letby's first defence team but not called to testify, disputed the panel's traumatic‑delivery explanation but maintained that there was no evidence of deliberate harm.
Like many other biologically active substances, norepinephrine exerts its effects by binding to and activating receptors located on the surface of cells. Two broad families of norepinephrine receptors have been identified, known as alpha and beta-adrenergic receptors. Alpha receptors are divided into subtypes α1 and α2; beta receptors into subtypes β1, β2, and β3. All of these function as G protein-coupled receptors, meaning that they exert their effects via a complex second messenger system. Alpha-2 receptors usually have inhibitory effects, but many are located pre-synaptically (i.e., on the surface of the cells that release norepinephrine), so the net effect of alpha-2 activation is often a decrease in the amount of norepinephrine released. Alpha-1 receptors and all three types of beta receptors usually have excitatory effects.
Sources: en.wikipedia.org
To slow this metabolic degradation and improve the drug's pharmacokinetic profile, researchers sought to replace the highly oxidizable pyridyl groups with more electron-deficient heterocyclic. This led to the following key structural optimizations:
In addition, they announced plans to conduct a phase 2b study of enobosarm at doses of 3 to 6 mg/day for this purpose in sarcopenic obese or overweight elderly individuals receiving GLP-1 receptor agonists. Enobosarm was developed by GTx, Inc., and is now being developed by Veru, Inc.
== Advantages and limitations == A major advantage of ABPP is the ability to monitor the availability of the enzyme active site directly, rather than being limited to protein or mRNA abundance. Ideal ABPs would target a large, but manageable, number of enzymes (tens to hundreds) to provide researchers with a global view of the functional state of the proteome. This degree of target promiscuity must be balanced by minimal cross-reactivity with unrelated proteins. Most ABPs achieve this combination of intraclass coverage and limited extraclass reactivity by coupling appropriate reactive groups with binding elements that recognize conserved mechanistic or structural features within enzyme active sites. Furthermore, ABPP could be used to target specific proteins which were previously viewed as undruggable targets. A disadvantage of ABPs is that their design is somewhat restricted by the need to attach an electrophile or photocrosslinker, which can limit chemical diversity. Another potential drawback is that covalent modification of the active site irreversibly inhibits the target enzyme. However, in many cases it is possible to use concentrations of ABP such that only a small fraction of the active enzyme pool is labeled, minimizing perturbation of overall enzymatic activity.
bars party States from placing weapons of mass destruction in Earth orbit, on the Moon, or any other celestial body; exclusively limits the use of the Moon and other celestial bodies to peaceful purposes, and expressly prohibits their use for testing weapons of any kind, conducting military maneuvers, or establishing military bases, installations, and fortifications; declares that the exploration of outer space shall be done to benefit all countries and shall be free for exploration and use by all the States; explicitly forbids any government from claiming a celestial resource such as the Moon or a planet, claiming that they are the common heritage of mankind, "not subject to national appropriation by claim of sovereignty, by means of use or occupation, or by any other means".
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.